Clofarabine

證據等級: L5

預測適應症: 10 個

Clofarabine: From Pediatric Acute Lymphoblastic Leukemia to Myeloid Leukemia

One-Sentence Summary

Clofarabine (Clolar/Evoltra) is a second-generation purine nucleoside analog, originally approved by the FDA (2004) and EMA (2006) for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1–21 years. The TxGNN model predicts it may be effective for Myeloid Leukemia (including AML and CML blast crisis), with 50+ clinical trials and 20 publications supporting this direction. The evidence base is exceptionally strong, anchored by a completed Phase 3 trial (NCT00703820, n=324), a large Phase 2/3 program (NCT00454480, n=2,000), and an ongoing randomized Phase 3 trial (FLUCLORIC, NCT05917405, n=302), placing this at the highest evidence level (L1).

Quick Overview

Item	Content
Original Indication	Relapsed/refractory acute lymphoblastic leukemia (ALL) in pediatric patients (context from FDA/EMA approval; no EU authorizations recorded in current database)
Predicted New Indication	Myeloid Leukemia
TxGNN Prediction Score	99.88%
Evidence Level	L1
EU Market Status	Not confirmed (0 authorizations in current database)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Clofarabine is a halogenated purine nucleoside analog specifically engineered to combine the best pharmacological properties of fludarabine and cladribine while overcoming their respective weaknesses. Once taken up by cells, it is phosphorylated by intracellular deoxycytidine kinase (DCK) to its active triphosphate form (CloFATP). CloFATP exerts cytotoxicity through two complementary mechanisms: first, inhibition of ribonucleotide reductase, which depletes the intracellular pool of deoxyribonucleoside triphosphates (dNTPs) required for DNA synthesis; and second, direct inhibition of DNA polymerases α and ε, halting replication and repair. Beyond these actions, clofarabine disrupts mitochondrial membrane integrity, triggering the intrinsic apoptosis pathway in a manner independent of cell-cycle phase. Its resistance to deamination by adenosine deaminase and to phosphorolysis also gives it superior metabolic stability compared to earlier-generation analogs.

The mechanistic link to myeloid leukemia is direct and well-characterized. AML blast cells characteristically overexpress DCK, making them highly efficient at converting clofarabine to its active form — this is the same biochemical vulnerability that makes ALL blasts sensitive, and it is equally prominent in the myeloid lineage. Both AML and ALL share the key features of rapid blast proliferation and heavy reliance on de novo DNA synthesis, making the purine nucleoside analog class broadly effective across acute leukemia subtypes. The pharmacological rationale for extending clofarabine’s use from lymphoid to myeloid leukemia is therefore straightforward.

Clinical validation of this mechanistic reasoning is extensive. The AML08 trial (Phase 3, n=324) demonstrated that a clofarabine-based induction regimen can directly replace conventional anthracycline-etoposide combinations in childhood AML without compromising remission rates. The NCT00454480 program (Phase 2/3, n=2,000) explored clofarabine across a broad spectrum of older AML patients. The ongoing FLUCLORIC trial (Phase 3, n=302) is currently testing whether replacing fludarabine with clofarabine in pre-transplant conditioning improves outcomes in AML patients — retrospective data strongly favor clofarabine in this setting. Together, these studies represent the most robust translational bridge from the original ALL indication to the myeloid leukemia context.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00454480	Phase 2/3	Completed	2,000	Largest clofarabine AML programme: evaluated multiple drug combinations (including gemtuzumab ozogamicin and tipifarnib) in older AML and high-risk MDS patients; established clofarabine as a viable backbone for elderly-specific regimens
NCT00703820	Phase 3	Completed	324	AML08: randomized Phase 3 in childhood AML comparing clofarabine+cytarabine versus conventional daunorubicin+etoposide induction; demonstrated clofarabine can replace anthracyclines and etoposide with comparable efficacy
NCT05917405	Phase 2/3	Recruiting	302	FLUCLORIC: ongoing randomized Phase 3 comparing clofarabine/busulfan vs. fludarabine/busulfan as reduced-intensity conditioning before allogeneic SCT in AML; retrospective data favor clofarabine for anti-leukemic activity
NCT00098033	Phase 2	Completed	64	Phase 2 pharmacodynamic study in AML, ALL, and CML accelerated/blast phase; established single-agent antileukemic activity and provided foundational pharmacodynamic data
NCT01794702	Phase 1/2	Completed	65	Decitabine priming followed by clofarabine/idarubicin/cytarabine (CIA) in acute leukemia; demonstrated that epigenetic sensitization enhances clofarabine-based combination efficacy
NCT01025154	Phase 2	Completed	63	Clofarabine+idarubicin+cytarabine (CIA) as induction in younger AML patients (18–60 years); assessed complete remission rates and safety of this triplet combination
NCT00602225	Phase 1/2	Completed	50	Dose escalation of clofarabine+cytarabine+G-CSF priming in relapsed/refractory AML; established optimal dosing schedule for the CLAG-like regimen
NCT00924443	Phase 2	Completed	69	Clofarabine monotherapy in older AML patients unsuitable for intensive chemotherapy; key trial supporting use in a population with limited treatment options
NCT00067028	Phase 2	Completed	116	Randomized comparison of three clofarabine-containing regimens (with idarubicin and/or cytarabine) in first relapse or primary refractory AML and high-grade MDS
NCT01252667	Phase 2	Completed	44	Clofarabine+low-dose TBI as conditioning for allogeneic PBSCT in AML; aimed to improve 6-month relapse rates following non-myeloablative transplant conditioning

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31246522	2019	RCT	J Clin Oncology	AML08 Phase 3: Clofarabine+cytarabine can replace daunorubicin+etoposide in childhood AML induction; equivalent remission rates with reduced anthracycline cardiotoxicity exposure
36336258	2023	Cohort	Transplantation and Cellular Therapy	Clofarabine+busulfan (Clo/Bu4) myeloablative conditioning for active myeloid malignancies: acceptable toxicity profile with meaningful anti-leukemic activity in patients aged ≤70 years
32187883	2020	Clinical Study	Cancer Medicine	CLAM regimen (clofarabine+cytarabine+mitoxantrone) in R/R AML: high complete response rates and effective bridging to allogeneic HSCT in a Phase 2 study
31905904	2019	Clinical Study	Cancers	CLARA consolidation (clofarabine-based) vs. high-dose cytarabine in younger AML: clofarabine significantly improves relapse-free survival in patients with micro-complex karyotype
22957815	2013	Review	Leukemia & Lymphoma	Comprehensive review of clofarabine in AML: mechanism of action, pharmacology, and clinical data across monotherapy and combination strategies in first-line and salvage settings
25457773	2015	Review	Crit Rev Oncology/Hematology	Role of clofarabine in adult AML: development from monotherapy to multi-drug combinations; summarizes promising results across multiple Phase 1/2 trial programs
31637757	2020	Clinical Study	American J Hematology	Phase I/II multisite trial: clofarabine+2 Gy TBI as non-myeloablative conditioning for allogeneic HCT in AML; improved 6-month relapse rate without excess toxicity
18756533	2008	Clinical Study	Cancer	Clofarabine combinations with cytarabine and idarubicin as AML salvage therapy; established feasibility and efficacy with manageable toxicity in heavily pre-treated patients
29773602	2018	Clinical Study	Haematologica	Phase IB: clofarabine+high-dose cytarabine+liposomal daunorubicin in pediatric R/R AML; identified recommended Phase 2 dose, demonstrating combinability with anthracycline-containing regimens
21182488	2011	Review	Current Medicinal Chemistry	Novel agents for AML including clofarabine: positions clofarabine among next-generation nucleoside analogs with superior stability vs. fludarabine and cladribine

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Purine nucleoside analog (second-generation halogenated adenosine analog; classified as antimetabolite)
Myelosuppression Risk	High — Clofarabine causes profound and prolonged myelosuppression; neutropenia, thrombocytopenia, and anemia are expected in virtually all patients receiving therapeutic doses; neutropenic fever and opportunistic infections are common serious adverse events
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential (at minimum weekly during active treatment), hepatic function tests (ALT, AST, bilirubin), renal function (serum creatinine, eGFR), serum electrolytes (K⁺, Mg²⁺, PO₄³⁻), signs of systemic inflammatory response syndrome (SIRS) or capillary leak syndrome
Handling Protection	Must follow institutional cytotoxic drug handling regulations; personal protective equipment (PPE) required for preparation and administration; closed-system drug transfer devices (CSTDs) recommended

Safety Considerations

Please refer to the SmPC (Summary of Product Characteristics) for complete safety information. No formal safety data (key warnings, contraindications, or drug-drug interactions) were captured in the current evidence pack for this drug.

Based on published clinical literature and the known class profile of purine nucleoside analogs, clinicians should be aware of the following safety signals associated with clofarabine:

Severe myelosuppression: Expected in all patients; prolonged neutropenia increases infectious risk
Hepatotoxicity: Elevated transaminases and hyperbilirubinemia have been reported; dose modification may be required
Systemic inflammatory response / capillary leak syndrome: A recognized risk, particularly during rapid blast lysis; may require corticosteroid prophylaxis
Opportunistic infections: Including fungal and bacterial infections secondary to prolonged neutropenia

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The evidence supporting clofarabine in myeloid leukemia is among the most robust in this repurposing dataset. A completed Phase 3 randomized trial (AML08, n=324) has already demonstrated that clofarabine-based regimens are equivalent to conventional anthracycline-based induction in childhood AML, and the ongoing FLUCLORIC Phase 3 trial (n=302) is actively testing its superiority in pre-transplant conditioning. The mechanistic rationale — AML blast overexpression of DCK enabling highly efficient clofarabine phosphorylation — is well-established and directly parallels the pharmacology underlying its approved ALL indication.

To proceed, the following is needed:

Safety data reconciliation: Obtain the full SmPC / EMA Product Information for Evoltra (clofarabine) to formally document warnings, contraindications, and drug interactions for the safety assessment stage
EU market authorization verification: Confirm current EU registration status — clofarabine (Evoltra, Sanofi/Genzyme) received EMA approval in 2006 for pediatric ALL but product availability may have changed; verify against current EMA database
MOA formal documentation: Retrieve complete DrugBank mechanistic profile (DB00631) to satisfy the formal pharmacological data requirement
Patient population definition: Specify target subpopulation for this indication (newly diagnosed AML vs. R/R AML; pediatric vs. adult; transplant-eligible vs. ineligible) to focus the clinical development or access pathway strategy
Competitive landscape assessment: Evaluate current position of clofarabine-based regimens relative to recently approved AML therapies (venetoclax combinations, FLT3 inhibitors, IDH inhibitors) to identify best positioning strategy
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.